Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bagby

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Cell Death & Disease|June 10, 2020
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsNabanita Mukherjee, Jenette Skees, Kaleb J Todd, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Molecular Cancer Therapeutics|December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid TumorsJennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
Molecular Cancer Therapeutics|October 22, 2017
ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> IsoformsKasey L Couts, Judson Bemis, Jacqueline A Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal CancerRobert W Lentz, Tyler J Friedrich, Patrick J Blatchford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid TumorsS Lindsey Davis, Anastasia A Ionkina, Stacey M Bagby, et al.
Cancer Research Communications|October 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerRobert W Lentz, Julie Lang, Todd M Pitts, et al.
International Journal of Cancer|July 13, 2024
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingJacqueline A Turner, Robert J Van Gulick, William A Robinson, et al.
Frontiers in Immunology|April 15, 2021
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell PhenotypesJuan A Marín-Jiménez, Anna Capasso, Matthew S Lewis, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Cell Death & Disease|June 10, 2020
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsNabanita Mukherjee, Jenette Skees, Kaleb J Todd, et al.
Frontiers in Oncology|November 24, 2022
Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse modelsJulie Lang, Alexis D Leal, Juan A Marín-Jiménez, et al.
Molecular Cancer Therapeutics|December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid TumorsJennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
Molecular Cancer Therapeutics|October 22, 2017
ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> IsoformsKasey L Couts, Judson Bemis, Jacqueline A Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal CancerRobert W Lentz, Tyler J Friedrich, Patrick J Blatchford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2020
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid TumorsS Lindsey Davis, Anastasia A Ionkina, Stacey M Bagby, et al.
Cancer Research Communications|October 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerRobert W Lentz, Julie Lang, Todd M Pitts, et al.
International Journal of Cancer|July 13, 2024
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingJacqueline A Turner, Robert J Van Gulick, William A Robinson, et al.
Frontiers in Immunology|April 15, 2021
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell PhenotypesJuan A Marín-Jiménez, Anna Capasso, Matthew S Lewis, et al.
Pageof 14